536 related articles for article (PubMed ID: 28156185)
1. Evidence of activation of the Nrf2 pathway in multiple sclerosis patients treated with delayed-release dimethyl fumarate in the Phase 3 DEFINE and CONFIRM studies.
Gopal S; Mikulskis A; Gold R; Fox RJ; Dawson KT; Amaravadi L
Mult Scler; 2017 Dec; 23(14):1875-1883. PubMed ID: 28156185
[TBL] [Abstract][Full Text] [Related]
2. Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis.
Kappos L; Giovannoni G; Gold R; Phillips JT; Arnold DL; Hotermans C; Zhang A; Viglietta V; Fox RJ;
Eur J Neurol; 2015 Apr; 22(4):664-71. PubMed ID: 25557371
[TBL] [Abstract][Full Text] [Related]
3. Dimethylfumarate attenuates restenosis after acute vascular injury by cell-specific and Nrf2-dependent mechanisms.
Oh CJ; Park S; Kim JY; Kim HJ; Jeoung NH; Choi YK; Go Y; Park KG; Lee IK
Redox Biol; 2014; 2():855-64. PubMed ID: 25009787
[TBL] [Abstract][Full Text] [Related]
4. Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies.
Kita M; Fox RJ; Gold R; Giovannoni G; Phillips JT; Sarda SP; Kong J; Viglietta V; Sheikh SI; Okwuokenye M; Kappos L
Clin Ther; 2014 Dec; 36(12):1958-1971. PubMed ID: 25315404
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS).
Gold R; Giovannoni G; Phillips JT; Fox RJ; Zhang A; Meltzer L; Kurukulasuriya NC
Mult Scler; 2015 Jan; 21(1):57-66. PubMed ID: 24990854
[TBL] [Abstract][Full Text] [Related]
6. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway.
Scannevin RH; Chollate S; Jung MY; Shackett M; Patel H; Bista P; Zeng W; Ryan S; Yamamoto M; Lukashev M; Rhodes KJ
J Pharmacol Exp Ther; 2012 Apr; 341(1):274-84. PubMed ID: 22267202
[TBL] [Abstract][Full Text] [Related]
7. Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies.
Giovannoni G; Gold R; Fox RJ; Kappos L; Kita M; Yang M; Sarda SP; Zhang R; Viglietta V; Havrdova E
Clin Ther; 2015 Nov; 37(11):2543-51. PubMed ID: 26526385
[TBL] [Abstract][Full Text] [Related]
8. Dimethyl Fumarate and Monomethyl Fumarate Promote Post-Ischemic Recovery in Mice.
Yao Y; Miao W; Liu Z; Han W; Shi K; Shen Y; Li H; Liu Q; Fu Y; Huang D; Shi FD
Transl Stroke Res; 2016 Dec; 7(6):535-547. PubMed ID: 27614618
[TBL] [Abstract][Full Text] [Related]
9. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies.
Havrdova E; Giovannoni G; Gold R; Fox RJ; Kappos L; Phillips JT; Okwuokenye M; Marantz JL
Eur J Neurol; 2017 May; 24(5):726-733. PubMed ID: 28328179
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.
Fernández Ó; Giovannoni G; Fox RJ; Gold R; Phillips JT; Potts J; Okwuokenye M; Marantz JL
Clin Ther; 2017 Aug; 39(8):1671-1679. PubMed ID: 28751099
[TBL] [Abstract][Full Text] [Related]
11. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study.
Miller DH; Fox RJ; Phillips JT; Hutchinson M; Havrdova E; Kita M; Wheeler-Kingshott CA; Tozer DJ; MacManus DG; Yousry TA; Goodsell M; Yang M; Zhang R; Viglietta V; Dawson KT;
Neurology; 2015 Mar; 84(11):1145-52. PubMed ID: 25681448
[TBL] [Abstract][Full Text] [Related]
12. Donor variability may mask dimethyl fumarate's effects on nuclear factor E2-related factor 2 in human peripheral blood mononuclear cells.
Fiedler SE; Kerns AR; Tsang C; Love HN; Salinthone S
BMC Res Notes; 2017 Nov; 10(1):553. PubMed ID: 29096692
[TBL] [Abstract][Full Text] [Related]
13. Dimethyl Fumarate Protects Neural Stem/Progenitor Cells and Neurons from Oxidative Damage through Nrf2-ERK1/2 MAPK Pathway.
Wang Q; Chuikov S; Taitano S; Wu Q; Rastogi A; Tuck SJ; Corey JM; Lundy SK; Mao-Draayer Y
Int J Mol Sci; 2015 Jun; 16(6):13885-907. PubMed ID: 26090715
[TBL] [Abstract][Full Text] [Related]
14. Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study.
Arnold DL; Gold R; Kappos L; Bar-Or A; Giovannoni G; Selmaj K; Yang M; Zhang R; Stephan M; Sheikh SI; Dawson KT
J Neurol; 2014 Sep; 261(9):1794-802. PubMed ID: 24989666
[TBL] [Abstract][Full Text] [Related]
15. Protective effects of monomethyl fumarate at the inflamed blood-brain barrier.
Lim JL; van der Pol SM; Di Dio F; van Het Hof B; Kooij G; de Vries HE; van Horssen J
Microvasc Res; 2016 May; 105():61-9. PubMed ID: 26679389
[TBL] [Abstract][Full Text] [Related]
16. Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study.
Arnold DL; Gold R; Kappos L; Bar-Or A; Giovannoni G; Selmaj K; Yang M; Zhang R; Stephan M; Sheikh SI; Dawson KT
J Neurol; 2014 Dec; 261(12):2429-37. PubMed ID: 25270680
[TBL] [Abstract][Full Text] [Related]
17. [Extending therapeutic possibilities in relapsing-remitting multiple sclerosis: dimethyl fumarate].
Matolcsi J; Rózsa C
Ideggyogy Sz; 2015 Jan; 68(1-2):7-14. PubMed ID: 25842911
[TBL] [Abstract][Full Text] [Related]
18. Dimethyl fumarate activates the prostaglandin EP2 receptor and stimulates cAMP signaling in human peripheral blood mononuclear cells.
Fiedler SE; Kerns AR; Tsang C; Tsang V; Bourdette D; Salinthone S
Biochem Biophys Res Commun; 2016 Jun; 475(1):19-24. PubMed ID: 27157139
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and Bioavailability of Monomethyl Fumarate Following a Single Oral Dose of Bafiertam™ (Monomethyl Fumarate) or Tecfidera
Lategan TW; Wang L; Sprague TN; Rousseau FS
CNS Drugs; 2021 May; 35(5):567-574. PubMed ID: 33797063
[TBL] [Abstract][Full Text] [Related]
20. Fumaric acid esters promote neuronal survival upon ischemic stress through activation of the Nrf2 but not HIF-1 signaling pathway.
Lin-Holderer J; Li L; Gruneberg D; Marti HH; Kunze R
Neuropharmacology; 2016 Jun; 105():228-240. PubMed ID: 26801077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
